Hepatocellular adenoma risk factors: Difference between revisions
Jump to navigation
Jump to search
Nawal Muazam (talk | contribs) No edit summary |
Nawal Muazam (talk | contribs) No edit summary |
||
| Line 5: | Line 5: | ||
The most potent risk factor in the development of hepatocellular adenoma is use of oral contraceptive pills.<ref name=risk>How do oral contraceptives affect liver cancer risk. National Cancer Institute 2015. http://www.cancer.gov/about-cancer/causes-prevention/risk/hormones/oral-contraceptives-fact-sheet</ref> | The most potent risk factor in the development of hepatocellular adenoma is use of oral contraceptive pills.<ref name=risk>How do oral contraceptives affect liver cancer risk. National Cancer Institute 2015. http://www.cancer.gov/about-cancer/causes-prevention/risk/hormones/oral-contraceptives-fact-sheet</ref> | ||
==Hepatocellular adenoma risk factors== | ==Hepatocellular adenoma risk factors== | ||
The most potent risk factor in the development of hepatocellular adenoma is use of oral contraceptive pills.<ref name=risk>How do oral contraceptives affect liver cancer risk. National Cancer Institute 2015. http://www.cancer.gov/about-cancer/causes-prevention/risk/hormones/oral-contraceptives-fact-sheet</ref><ref name="pmid18333188">{{cite journal| author=Barthelmes L, Tait IS| title=Liver cell adenoma and liver cell adenomatosis. | journal=HPB (Oxford) | year= 2005 | volume= 7 | issue= 3 | pages= 186-96 | pmid=18333188 | doi=10.1080/13651820510028954 | pmc=PMC2023950 | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=18333188 }} </ref> | * The most potent risk factor in the development of hepatocellular adenoma is use of oral contraceptive pills. | ||
* The risk is proportional to:<ref name=risk>How do oral contraceptives affect liver cancer risk. National Cancer Institute 2015. http://www.cancer.gov/about-cancer/causes-prevention/risk/hormones/oral-contraceptives-fact-sheet</ref><ref name="pmid18333188">{{cite journal| author=Barthelmes L, Tait IS| title=Liver cell adenoma and liver cell adenomatosis. | journal=HPB (Oxford) | year= 2005 | volume= 7 | issue= 3 | pages= 186-96 | pmid=18333188 | doi=10.1080/13651820510028954 | pmc=PMC2023950 | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=18333188 }} </ref> | |||
:* Hormonal dose | |||
:* Duration of medication | |||
:*[[Drospirenone and Ethinyl estradiol]] | :*[[Drospirenone and Ethinyl estradiol]] | ||
:*[[Norethindrone acetate and Ethinyl estradiol]] | :*[[Norethindrone acetate and Ethinyl estradiol]] | ||
:*[[Norgestimate and Ethinyl estradiol]] | :*[[Norgestimate and Ethinyl estradiol]] | ||
:*[[Norgestrel and Ethinyl estradiol]] | :*[[Norgestrel and Ethinyl estradiol]] | ||
* | * Other risk factors include:<ref name="pmid18333188">{{cite journal| author=Barthelmes L, Tait IS| title=Liver cell adenoma and liver cell adenomatosis. | journal=HPB (Oxford) | year= 2005 | volume= 7 | issue= 3 | pages= 186-96 | pmid=18333188 | doi=10.1080/13651820510028954 | pmc=PMC2023950 | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=18333188 }} </ref> | ||
:* [[Clomiphene]] | |||
:* Methyl testosterone | |||
:* [[Danazol]] | |||
:* [[Klinefelter's syndrome]] | |||
:* Types I, III and IV [[glycogen storage disease]] | |||
:* [[Familial adenomatous polyposis]] | |||
==Risk factors for malignant transformation== | ==Risk factors for malignant transformation== | ||
The risk factor for malignant transformation of hepatic adenoma to hepatocellular carcinoma is:<ref name="pmid25786843">{{cite journal| author=Aamann L, Schultz N, Fallentin E, Hamilton-Dutoit S, Vogel I, Grønbæk H| title=[Hepatocellular adenoma - new classification and recommendations]. | journal=Ugeskr Laeger | year= 2015 | volume= 177 | issue= 12 | pages= | pmid=25786843 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=25786843 }} </ref> | The risk factor for malignant transformation of hepatic adenoma to hepatocellular carcinoma is:<ref name="pmid25786843">{{cite journal| author=Aamann L, Schultz N, Fallentin E, Hamilton-Dutoit S, Vogel I, Grønbæk H| title=[Hepatocellular adenoma - new classification and recommendations]. | journal=Ugeskr Laeger | year= 2015 | volume= 177 | issue= 12 | pages= | pmid=25786843 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=25786843 }} </ref> | ||
Revision as of 14:02, 2 November 2015
|
Hepatocellular adenoma Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Hepatocellular adenoma risk factors On the Web |
|
American Roentgen Ray Society Images of Hepatocellular adenoma risk factors |
|
Risk calculators and risk factors for Hepatocellular adenoma risk factors |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1];Associate Editor(s)-in-Chief: Nawal Muazam M.D.[2]
Overview
The most potent risk factor in the development of hepatocellular adenoma is use of oral contraceptive pills.[1]
Hepatocellular adenoma risk factors
- The most potent risk factor in the development of hepatocellular adenoma is use of oral contraceptive pills.
- The risk is proportional to:[1][2]
- Hormonal dose
- Duration of medication
- Other risk factors include:[2]
- Clomiphene
- Methyl testosterone
- Danazol
- Klinefelter's syndrome
- Types I, III and IV glycogen storage disease
- Familial adenomatous polyposis
Risk factors for malignant transformation
The risk factor for malignant transformation of hepatic adenoma to hepatocellular carcinoma is:[3]
- Gender (men)
- Size (> 8 cm)
- Subtype (beta-catenin-activated HCA)
References
- ↑ 1.0 1.1 How do oral contraceptives affect liver cancer risk. National Cancer Institute 2015. http://www.cancer.gov/about-cancer/causes-prevention/risk/hormones/oral-contraceptives-fact-sheet
- ↑ 2.0 2.1 Barthelmes L, Tait IS (2005). "Liver cell adenoma and liver cell adenomatosis". HPB (Oxford). 7 (3): 186–96. doi:10.1080/13651820510028954. PMC 2023950. PMID 18333188.
- ↑ Aamann L, Schultz N, Fallentin E, Hamilton-Dutoit S, Vogel I, Grønbæk H (2015). "[Hepatocellular adenoma - new classification and recommendations]". Ugeskr Laeger. 177 (12). PMID 25786843.